Clinical Trial Update: Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

View source ↗

Summary

Real-world outcomes in melanoma patients treated with neoadjuvant nivolumab+relatlimab versus nivolumab+ipilimumab; the study is completed and sponsored by Bris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Status: COMPLETED